PDS Biotechnology (NASDAQ:PDSB) Price Target Lowered to $16.00 at Alliance Global Partners

PDS Biotechnology (NASDAQ:PDSB – Get Rating) had its price target reduced by Alliance Global Partners from $18.00 to $16.00 in a research report sent to investors on Friday, The Fly reports.

A number of other equities research analysts have also issued reports on the stock. Noble Financial reissued a buy rating and issued a $22.00 price target on shares of PDS Biotechnology in a report on Thursday. StockNews.com raised shares of PDS Biotechnology to a sell rating in a report on Saturday, April 9th. Finally, Zacks Investment Research lowered shares of PDS Biotechnology from a hold rating to a sell rating in a report on Friday. Two investment analysts have rated the stock with a sell rating and six have given a buy rating to the company’s stock. According to MarketBeat, PDS Biotechnology has a consensus rating of Buy and a consensus target price of $17.00.

NASDAQ:PDSB traded up $0.73 during trading hours on Friday, reaching $4.56. The company’s stock had a trading volume of 552,690 shares, compared to its average volume of 232,316. The firm has a 50-day simple moving average of $5.66 and a 200-day simple moving average of $7.26. PDS Biotechnology has a 1 year low of $3.47 and a 1 year high of $17.85.

PDS Biotechnology (NASDAQ:PDSB – Get Rating) last issued its earnings results on Wednesday, May 11th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.09). During the same period in the prior year, the firm posted ($0.14) EPS. Sell-side analysts anticipate that PDS Biotechnology will post -0.98 EPS for the current year.

Several institutional investors and hedge funds have recently made changes to their positions in PDSB. Bank of America Corp DE boosted its stake in shares of PDS Biotechnology by 7,093.1% during the 4th quarter. Bank of America Corp DE now owns 4,172 shares of the company’s stock valued at $34,000 after purchasing an additional 4,114 shares in the last quarter. UBS Group AG bought a new stake in shares of PDS Biotechnology during the 3rd quarter valued at about $44,000. Minot Wealth Management LLC bought a new stake in shares of PDS Biotechnology during the 1st quarter valued at about $62,000. Andesa Financial Management Inc. purchased a new position in PDS Biotechnology during the 1st quarter valued at about $77,000. Finally, GSA Capital Partners LLP purchased a new position in PDS Biotechnology during the 1st quarter valued at about $89,000. 20.94% of the stock is currently owned by hedge funds and other institutional investors.

About PDS Biotechnology (Get Rating)

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer.

Read More